BlueWave Therapeutics: cancer treatment by targeted radionuclide therapy

DEFINING THE ART OF CANCER TREATMENT

NEW HOPE FOR POOR PROGNOSIS CANCER PATIENTS

THERAPEUTIC APPROACH

Blue Wave Therapeutics is developing an innovative biopolymer-radionuclide targeted platform technology, to target residual cancer cells of patients with low survival rates. The deadliest of brain cancers, glioblastoma, is Blue Wave Therapeutics’ first targeted indication.

INNOVATIVE, EFFECTIVE AND SAFE

Radionuclide therapy has shown excellent results as a targeted treatment for various cancer types, with a benign safety profile.

LOCALLY ADMINISTERED AND TARGETED

The radio-charged polymer is locally administered with a one-time, easy-to-use injection in situ. The biopolymer specifically binds to the tumor cells.

SUITABLE FOR MULTIPLE CANCERS

Multiple cancers with a high medical need, i.e. pancreatic, breast, cervical, colon and lung cancer, can be targeted through our proprietary platform technology.

CONVENIENCE FOR PATIENTS

In glioblastoma the use of this technology is intended as adjuvant therapy, i.e. given after surgery with no need of subsequent removal.

THE NEXT GENERATION ADJUVANT THERAPY FOR GLIOBLASTOMA

Glioblastoma is a devastating disease. It is the most aggressive primary brain tumor with serious unmet medical need, as it metastasizes quickly in the brain and can double the size in 10 days. Despite available therapies, the prognosis is extremely poor. The majority of patients do not survive for more than two years following diagnosis, and the median survival is generally less than a year. The average 5-year survival rate is less than 3%.

The standard treatment is surgery followed by external beam radiation therapy and chemotherapy. However, healthy brain tissue is also receiving a considerable dose when treated, thus limiting the therapeutic efficacy of these treatments.